3',4'-Methylenedioxy-α-pyrrolidinobutiophenone
Synthetic stimulant drug
3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP) is a synthetic stimulant of the cathinone class. It is chemically related to pyrrolidinophenone derivatives and is known for its psychoactive effects. MDPBP is often encountered in the context of designer drugs and has been subject to legal control in various jurisdictions.
Chemical Structure and Properties[edit]

MDPBP is characterized by the presence of a methylenedioxy group attached to the phenyl ring, which is a common feature in many psychoactive substances. The compound also contains a pyrrolidinyl group, which is responsible for its stimulant properties. The full chemical name is 1-(3,4-methylenedioxyphenyl)-2-(pyrrolidin-1-yl)butan-1-one.
Pharmacology[edit]
MDPBP acts as a central nervous system stimulant. It is believed to exert its effects primarily by inhibiting the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This mechanism is similar to that of other stimulants such as amphetamines and cocaine.
Effects and Usage[edit]
The effects of MDPBP are similar to those of other stimulant drugs, including increased alertness, euphoria, and enhanced physical performance. However, it can also lead to adverse effects such as anxiety, paranoia, and cardiovascular issues. Due to its potential for abuse and harmful effects, MDPBP is not approved for medical use.
Legal Status[edit]
MDPBP has been classified as a controlled substance in several countries due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting new psychoactive substances (NPS) or "legal highs."
Synthesis[edit]
The synthesis of MDPBP involves the reaction of 3,4-methylenedioxyphenyl-2-propanone with pyrrolidine and a butanone derivative. The process requires careful control of reaction conditions to ensure the desired product is obtained.
Health Risks[edit]
The use of MDPBP can lead to serious health risks, including cardiovascular complications, neurological effects, and potential for addiction. Users may experience tachycardia, hypertension, and hyperthermia. Long-term use can result in psychological dependence and cognitive deficits.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian